

SenzaGen—next generation safety testing is called GARD™

The technology

GARD[™] platform

GARD (Genomic Allergen Rapid Detection) is an *in vitro* platform for assessment of various toxicological endpoints using genomic-based technology. The GARD platform offers a portfolio of tests sharing the same scientific principle but focusing on different toxicological endpoints.

GARDskinTM is the first ready-for-market application from the portfolio and is a robust *in vitro* skin sensitization assay with the highest accuracy on the market.⁽¹⁾

GARDpotencyTM is an add-on assay to GARDskin and is a first-in-class *in vitro* test to perform CLP 1A, 1B potency classification.^[2]

Our pipeline projects include GARDair for respiratory sensitisation, GARD for respiratory irritation, GARD for proteins and GARD for complex mixtures.

The GARDair project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 756014.



The company

SenzaGen. Senzagen is a spin-out company from Lund University located in the south of Sweden with expertise in immunology, information technology and genomics. The company is dedicated to developing innovative *in vitro* methods for safety testing of chemicals and ingredients. SenzaGen performs the *in vitro* GARD test in its own laboratory and through licenced partners around the world.

Contact us

Peter Sandberg, Director of Sales, SenzaGen AB Phone: +46 708 204 481 Email: peter.sandberg@senzagen.com

SenzaGen AB Medicon Village, Scheelevägen 2, 22 381 Lund, Sweden Office: +46 46 275 62 00 Email: info@senzagen.com www. senzagen.com


References

Johansson et al., GARD in-house validation – A proof of concept. Tox Sci, 2014
Zeller et al., The GARD platform for potency assessment of skin sensitizing chemicals. ALTEX, 2017




How to **GARD**[™] your product in six steps

GARD Input Finder




Grown SenzaCells.

•



Add different concentrations of the test substance to the cells.



Determine the concentration of the test substance where the cells react and 90% survive.

SENZAGEN

